Sequent Scientific Ltd Stock Price Today (NSE: SEQUENT)
Fundamental Score
Sequent Scientific Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sequent Scientific Ltd share price today is ₹188.78, up +0.00% on NSE/BSE as of 17 June 2026. Sequent Scientific Ltd (SEQUENT) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹5.60K (Cr). The 52-week high for SEQUENT share price is ₹257.85 and the 52-week low is ₹166.00. At a P/E ratio of 129.57x, SEQUENT is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 3.21% and a debt-to-equity ratio of 0.61.
Sequent Scientific Ltd Share Price Chart — NSE/BSE Historical Performance
Sequent Scientific Ltd share price chart: -13.96% return over the past month. 52-week high ₹257.85, 52-week low ₹166.00.
Sequent Scientific Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹185.40 | ₹192.50 | ₹185.00 | ₹188.78 | 9.65L (Cr) | |
| ₹186.54 | ₹187.12 | ₹178.13 | ₹179.89 | 10.40L (Cr) | |
| ₹190.01 | ₹194.76 | ₹188.00 | ₹188.43 | 5.46L (Cr) | |
| ₹192.00 | ₹194.69 | ₹189.00 | ₹189.71 | 5.92L (Cr) | |
| ₹191.15 | ₹199.40 | ₹191.15 | ₹195.32 | 7.97L (Cr) | |
| ₹195.10 | ₹195.78 | ₹190.50 | ₹192.50 | 7.45L (Cr) | |
| ₹196.65 | ₹198.73 | ₹190.90 | ₹194.67 | 8.26L (Cr) | |
| ₹196.06 | ₹199.30 | ₹190.71 | ₹197.30 | 9.69L (Cr) | |
| ₹194.74 | ₹199.10 | ₹191.45 | ₹196.06 | 6.95L (Cr) | |
| ₹199.00 | ₹200.82 | ₹195.00 | ₹195.32 | 5.00L (Cr) |
Sequent Scientific Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹202.20 | ₹208.98 | ₹178.13 | ₹188.78 | -6.64% | |
| ₹204.00 | ₹240.00 | ₹197.10 | ₹213.08 | +4.45% | |
| ₹208.44 | ₹211.39 | ₹188.00 | ₹203.61 | -2.32% | |
| ₹224.60 | ₹228.00 | ₹193.00 | ₹208.54 | -7.15% | |
| ₹215.99 | ₹257.85 | ₹210.57 | ₹223.46 | +3.46% | |
| ₹186.29 | ₹220.45 | ₹186.06 | ₹214.61 | +15.20% | |
| ₹168.55 | ₹209.00 | ₹168.55 | ₹186.29 | +10.53% | |
| ₹171.00 | ₹184.70 | ₹166.00 | ₹169.37 | -0.95% | |
| ₹192.75 | ₹197.00 | ₹171.00 | ₹171.97 | -10.78% | |
| ₹196.00 | ₹201.47 | ₹182.25 | ₹192.75 | -1.66% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Viyash (formerly Sequent) is a pricey bet on animal health leadership, with integration risks looming.
WHAT'S HAPPENING NOW
No major catalysts found after live search. Viyash Scientific (formerly Sequent Scientific) is navigating a transitional phase, with a focus on animal health and the integration of Viyash Life Sciences. The company officially changed its name to Viyash Scientific on January 8, 2026.
CORE STORY
- Merger with Viyash Life Sciences completed
- Focus on higher-margin animal health business
- Overall growth in Indian pharma exports
- Successful product launches in animal health
- Higher-than-expected synergies from the merger
- Positive regulatory developments
- High valuation relative to peers
- Integration risks with Viyash Life Sciences
- Micro-cap liquidity risk
FII and DII holdings have slightly decreased. Promoter holding remains high at 52.33%.
Indian pharma sector projected to reach $130 billion by 2030, driven by global demand and innovation.
Free Cash Flow 5Y: ₹84.72 Cr
The next 3-6 months will be crucial for demonstrating successful integration and execution of the animal health strategy. Watch for margin expansion and new product launches.
Primary Thesis Risk
Failed integration of Viyash Life Sciences kills the growth story.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sequent Scientific Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sequent Scientific Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SEQUENT across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (504.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (15.01%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Cash Generation (₹84.72 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (52.33%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (3.21%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.47%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 129.57x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-20.84% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-20.72% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (2.40x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sequent Scientific Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sequent Scientific Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sequent Scientific LtdSequent Scienti...Selected✓ SEQUENT • 512529 | 34.5/100 | ₹188.78₹189 | ₹5604.57₹5604.57 | 129.57Average 129.6 Average | 3.21%Poor 3.21% Poor | 8.47%Poor 8.47% Poor | 0.61Good 0.6 Good | -20.72%Poor -20.72% Poor | 5.64%Good 5.64% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Sequent Scientific Ltd PE Ratio History
Historical price-to-earnings ratio for SEQUENT — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.85 | ₹208.54 | 245.3x |
| FY 2022 | ₹1.63 | ₹87.60 | 53.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sequent Scientific Ltd Dividend History
Annual cash dividends paid by SEQUENT — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹12.34 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Sequent Scientific Ltd Quarterly Performance
Latest quarterly metrics for SEQUENT — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
15.01%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
504.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
5.64%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-20.72%
Compounded annual net profit growth over 5 years
Sequent Scientific Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SEQUENT — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Sequent Scientific Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Sequent Scientific Ltd (SEQUENT) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Sequent Scientific Ltd
About SEQUENT (Sequent Scientific Ltd)
Sequent Scientific Ltd is a dynamic pharmaceutical company dedicated to animal health, operating across Europe, Asia, and beyond. Sequent specializes in the development, manufactur...ing, and distribution of a diverse range of finished dosage formulations designed to improve the well-being of various animal populations. From farm animals vital to global food security to cherished family pets, Sequent provides innovative healthcare solutions in key therapeutic areas, including targeted nutrition, effective pain relief, comprehensive parasite control, advanced antibiotic treatments, and specialized gut health products. With a commitment to scientific excellence and animal welfare, Sequent strives to meet the evolving needs of the veterinary community and animal owners worldwide. Beyond its core product offerings, Sequent Scientific extends its expertise through comprehensive analytical services, ensuring the safety, efficacy, and quality of its formulations. The company's dedication to innovation is further demonstrated by its bespoke VET formulation services, tailored to meet specific client needs and address unique challenges in animal healthcare. These services encompass research and development, formulation optimization, and regulatory support, enabling Sequent to partner with veterinary professionals and other stakeholders to deliver cutting-edge solutions. By combining scientific rigor with a deep understanding of animal physiology, Sequent develops precisely tailored formulations to optimize animal health and performance. Sequent Scientific distinguishes itself through a customer-centric approach, building strong relationships with veterinarians, livestock producers, and pet owners alike. The company's commitment to quality, reliability, and innovation has established it as a trusted partner in the animal health industry. With a focus on sustainability and ethical practices, Sequent is dedicated to promoting responsible animal healthcare solutions that benefit both animals and the environment. Formerly known as PI Drugs & Pharmaceuticals Ltd., Sequent Scientific's evolution reflects its unwavering dedication to advancing animal health through continuous improvement and scientific discovery.
Company Details
Key Leadership
Corporate Events
SEQUENT Share Price: Frequently Asked Questions
What is the current share price of Sequent Scientific Ltd?
Sequent Scientific Ltd (SEQUENT) trades at ₹188.78 on NSE and BSE. Market cap ₹5.60K (Cr). Educational data only.
What is the P/E ratio of Sequent Scientific Ltd?
Sequent Scientific Ltd has a P/E of 129.57x vs industry average 31.77x.
What is the Bull Run score for Sequent Scientific Ltd?
Sequent Scientific Ltd has a Bull Run score of 34.5/100 based on 25+ financial parameters.
Does Sequent Scientific Ltd pay dividends?
Sequent Scientific Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Sequent Scientific Ltd?
Sequent Scientific Ltd has ROE of 3.21%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sequent Scientific Ltd?
Sequent Scientific Ltd has debt-to-equity of 0.61.
Is Sequent Scientific Ltd a good investment?
Bull Run gives Sequent Scientific Ltd a score of 34.5/100. This is not investment advice — consult a SEBI-registered advisor.